Effects of Ethanolic Extract of on the Pharmacokinetics of Rosuvastatin in Rats

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2022 May 24

PMID 35607596

Authors

Qing Sun

Li Li

Quan Zhou

Affiliations

Soon will be listed here.

Abstract

Purpose: Wuzhi capsule (WZ) is a proprietary Chinese medicine prepared from the ethanolic extract of that is commonly used to treat liver injury. Statins are widely used in patients with hyperlipidemia, coronary heart disease, metabolic syndrome, type 2 diabetes mellitus, and nonalcoholic fatty liver disease. Co-administration of statins with WZ is possible in clinical practice. WZ has obvious inhibitory effects on the bioavailability of atorvastatin and simvastatin; however, the drug-herb interactions between WZ and rosuvastatin have not been addressed. We explored the effects of WZ on the pharmacokinetics of rosuvastatin in Sprague-Dawley rats to promote a rational use of statins.

Methods: Eighteen male rats were randomly and evenly divided into three groups: control group (gavage feeding of rosuvastatin 10 mg·kg), single dose group (gavage feeding of a single dose of WZ 150 mg·kg followed by rosuvastatin 10 mg·kg) and multiple doses group (gavage feeding of WZ 150 mg·kg for 7 days followed by rosuvastatin 10 mg·kg on the seventh day). Plasma samples were collected at different times before and after rosuvastatin administration. The other 18 female rats were tested the same way as the male rats. All samples were analyzed by a validated LC-MS/MS method, and the pharmacokinetic parameters were calculated using a non-compartmental model.

Results: In both male and female rats, there were no statistically significant differences in rosuvastatin pharmacokinetic parameters between the control group, the single dose group, and the multi-dose group.

Conclusion: Acute or long-term intake of WZ had no obvious effect on the pharmacokinetics of rosuvastatin, and therefore rosuvastatin could be used as an alternative to atorvastatin and simvastatin when WZ is clinically required in conjunction with statins. An appropriate pharmacodynamic study is needed to encourage the safe use of this combination.

Citing Articles

Mechanisms of intestinal pharmacokinetic natural product-drug interactions.

Oyanna V, Clarke J Drug Metab Rev. 2024; 56(3):285-301.

PMID: 39078118 PMC: 11606768. DOI: 10.1080/03602532.2024.2386597.

The chemical composition of Diwu YangGan capsule and its potential inhibitory roles on hepatocellular carcinoma by microarray-based transcriptomics.

Shi Q, He J, Chen G, Xu J, Zeng Z, Zhao X J Tradit Complement Med. 2024; 14(4):381-390.

PMID: 39035694 PMC: 11259662. DOI: 10.1016/j.jtcme.2023.12.002.

References

Kamal S, Khan M, Seth A, Cholankeril G, Gupta D, Singh U . Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2017; 112(10):1495-1505. DOI: 10.1038/ajg.2017.170. View

Deedwania P, Hunninghake D, Bays H, Jones P, Cain V, Blasetto J . Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005; 95(3):360-6. DOI: 10.1016/j.amjcard.2004.09.034. View

Wu L, Liu J, Hou J, Zhan T, Yuan L, Liu F . Interactions of the major effective components in Shengmai formula with breast cancer resistance protein at the cellular and vesicular levels. Biomed Pharmacother. 2020; 133:110939. DOI: 10.1016/j.biopha.2020.110939. View

Li J, Volpe D, Wang Y, Zhang W, Bode C, Owen A . Use of transporter knockdown Caco-2 cells to investigate the in vitro efflux of statin drugs. Drug Metab Dispos. 2011; 39(7):1196-202. DOI: 10.1124/dmd.111.038075. View

Hua W, Fang H, Hua W . Transepithelial transport of rosuvastatin and effect of ursolic acid on its transport in Caco-2 monolayers. Eur J Drug Metab Pharmacokinet. 2012; 37(3):225-31. DOI: 10.1007/s13318-012-0094-9. View

Kostapanos M, Milionis H, Elisaf M . Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs. 2010; 10(1):11-28. DOI: 10.2165/13168600-000000000-00000. View

Wei H, Tao X, Di P, Yang Y, Li J, Qian X . Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab Dispos. 2013; 41(7):1398-403. DOI: 10.1124/dmd.112.050302. View

Chen Z, Liu F, Zheng N, Guo M, Bao L, Zhan Y . Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development. Biomed Pharmacother. 2018; 110:285-293. DOI: 10.1016/j.biopha.2018.11.069. View

Guo C, Deng S, Yin J, Liu Z, Zhang W, Zhou H . Schisandrin A and B induce organic anion transporting polypeptide 1B1 transporter activity. Pharmazie. 2015; 70(1):29-32. View

10.

Basu S, Jana S, Patel V, Patel H . Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats. Phytother Res. 2012; 27(10):1548-56. DOI: 10.1002/ptr.4894. View

11.

Xue X, Qin X, Xu C, Zhong G, Wang Y, Huang M . Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. Phytother Res. 2012; 27(8):1255-9. DOI: 10.1002/ptr.4849. View

12.

Hua W, Hua W, Fang H . The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther. 2011; 30(5):e234-41. DOI: 10.1111/j.1755-5922.2011.00290.x. View

13.

Chen J, Lou H, Jiang B, Shao R, Yang D, Hu Y . Effects of Food and Gender on Pharmacokinetics of Rosuvastatin in a Chinese Population Based on 4 Bioequivalence Studies. Clin Pharmacol Drug Dev. 2019; 9(2):235-245. DOI: 10.1002/cpdd.706. View

14.

Lv J, Ren C, Hu Q . Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials. Ann Palliat Med. 2021; 10(11):11548-11557. DOI: 10.21037/apm-21-2673. View

15.

Wen J, Xiong Y . The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet. 2011; 36(4):205-11. DOI: 10.1007/s13318-011-0048-7. View

16.

Habte M, Melka D, Degef M, Menon M, Yifter H, Feyisa T . Comparison of Lipid Profile, Liver Enzymes, Creatine Kinase and Lactate Dehydrogenase Among Type II Diabetes Mellitus Patients on Statin Therapy. Diabetes Metab Syndr Obes. 2020; 13:763-773. PMC: 7090212. DOI: 10.2147/DMSO.S234382. View

17.

Kitamura S, Maeda K, Wang Y, Sugiyama Y . Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008; 36(10):2014-23. DOI: 10.1124/dmd.108.021410. View

18.

Ballantyne C, Stein E, Paoletti R, Southworth H, Blasetto J . Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003; 91(5A):25C-27C; discussion 28C. DOI: 10.1016/s0002-9149(03)00006-7. View

19.

Jose J . Statins and its hepatic effects: Newer data, implications, and changing recommendations. J Pharm Bioallied Sci. 2016; 8(1):23-8. PMC: 4766774. DOI: 10.4103/0975-7406.171699. View

20.

Lu Y, Hu Q, Chen L, Zhang H, Huang S, Xiong Y . Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3. Xenobiotica. 2018; 49(2):239-246. DOI: 10.1080/00498254.2018.1437647. View